This article was originally published in The Rose Sheet
National Toxicology Program is soliciting final public comment on diethanolamine as part of 11th Report on Carcinogens review process, agency says in Jan. 22 1Federal Register notice. Comments are due within 60 days of notice. NTP Executive Committee will be making final recommendations to list, delist or not to list ingredients in the RoC. NTP Board of Scientific Counselors RoC Subcommittee recommended in November that DEA not be included in the upcoming report slated for publication in 2004 (2"The Rose Sheet" Nov. 25, 2002, p. 5)...
You may also be interested in...
Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.